Patent Publication Number: US-2022211753-A1

Title: A pharmaceutical herbo-mineral metallic composition and a process for preparation thereof

Description:
FIELD 
     The present disclosure relates to a pharmaceutical herbo-mineral-metallic composition and a process for preparation thereof. Particularly, the present disclosure relates to a pharmaceutical herbo-mineral-metallic composition for improving quality of life and survival 
     ABBREVIATIONS 
     WBC: White blood cells.
 
SGOT: Serum glutamic oxaloacetic transaminase.
 
SGPT: Serum glutamic pyruvic transaminase.
 
SBDIASBD: The pharmaceutical herbo-mineral metallic composition of the present
 
disclosure
 
RSR: Respective survival rate
 
     QoL: Quality of Life 
     QLQ C 30: Quality of Life Questionnaire 
     Definitions 
     As used in the present disclosure, the following terms are generally intended to have the meaning as set forth below, except to the extent that the context in which they are used indicate otherwise. 
     Suvarna bhasma: The term “Suvarna bhasma” refers to “incinerated gold” prepared by incinerating gold. 
     Mouktik bhasma: The term “Mouktik bhasma” refers to “incinerated pearl” prepared by incinerating pearl. 
     Guduchi Sattva: The term “Guduchi Sattva” refers to an extract comprising mainly starch of  Tinospora cordifolia/sinensis/crispa/glabra  prepared by alcoholic, hydro-alcoholic or aqueous extraction method. 
     Suvarna: The term “Suvarna” refers to “24 Karat Gold”. 
     Mouktik: The term “Mouktik” refers to “Pearl”. 
     Vati: The term “Vati” refers to a method of medicine preparation in which herbs, minerals and metallic compounds are compressed into tablet form. 
     Trituration: The term “trituration” refers to either reducing the particle size of a substance or production of a homogeneous material by mixing component materials thoroughly or wet grinding any material with a liquid media like fresh juice or decoction etc. 
     Karnofsky score: The term “Karnofsky score” refers to the Karnofsky Performance Scale Index allows patients to be classified as to theft functional impairment 
     Symptom score: Symptom score of QLQ is indicative of symptomatology; hence decrease in symptom score represents both decrease in disease related symptoms and adverse effects of conventional treatment. 
     Function score: Functional score of QLQ signifies status of routine physical activities. Increase in functional scores represents improvement in QoL. 
     Global score: Global score of QLQ represents overall well-being of a patient. Increase in global scores represents improvement in QoL. 
     BACKGROUND 
     The background information herein below relates to the present disclosure but is not necessarily prior art. 
     Various diseases such as viral infections, allergic diseases, long term chronic diseases, exposure to toxic chemicals, etc. are known to cause debility in patients. Some of the examples of such diseases are HIV/AIDS, Chikengunia and other mutated viruses; allergic bronchitis, asthma; hazards like metal toxicity, mining etc. In most of these conditions, quality of life of the patients is hampered. In extreme conditions, it may cause permanent damage also. 
     A very obvious example of one such condition is cancer. Cancer is one of the leading causes of morbidity and mortality in developing and developed countries. The number of new cases is expected to rise over the next 2 decades. 
     The existing modalities of treatment of cancer include surgery, radiotherapy and chemotherapy. Advanced cancers often do not respond to even accelerated chemotherapy, thereby leaving very little option for treatment. Radiation and chemotherapy often cause deleterious side-effects interfering therapeutic schedule of these treatment modalities and often hamper Quality of Life of the patients. This also leads to debility of the patients. Even after conventional therapies, recurrence and metastasis are difficult to control resulting in low survival rate. 
     Efforts have been made to overcome the problem of debility, adverse side effects and limited survival by using alternative or adjunct therapies. However, these therapies used so far did not show effective outcome with respect to above problems. 
     Therefore, there is felt a need to provide a selected combination of herbal, mineral and metallic compositions, that mitigates the aforestated problems. 
     OBJECTS 
     Some of the objects of the present disclosure, which at least one embodiment herein satisfies, are as follows: 
     An object of the present disclosure is to ameliorate one or more problems of the prior art or to at least provide a useful alternative. 
     Another object of the present disclosure is to provide a pharmaceutical herbo-mineral metallic composition. 
     Yet another object of the present disclosure is to provide a process for preparing a pharmaceutical herbo-mineral metallic composition 
     Yet another object of the present disclosure is to provide a pharmaceutical herbo-mineral metallic composition that improves and maintains quality of life of cancer patients by alleviating adverse effects due to chemotherapy and radiotherapy. 
     Still another object of the present disclosure is to provide a pharmaceutical herbo-mineral metallic composition that increases Disease Free Survival (DFS) or Overall Survival (OS) of cancer patients. 
     Other objects and advantages of the present disclosure will be more apparent from the following description, which is not intended to limit the scope of the present disclosure. 
     SUMMARY 
     The present disclosure provides a pharmaceutical herbo-mineral-metallic composition comprising Suvarna bhasma in an amount ranging from 2 wt % to 7 wt % of the total weight of the composition, Mouktik bhasma in an amount ranging from 20 wt % to 35 wt % of the total weight of the composition, Guduchi sattva in an amount ranging from 45 wt % to 60 wt % of the total weight of the composition, and at least one excipient in an amount ranging from 5 wt % to 30 wt % of the total weight of the composition. 
     In an embodiment of the present disclosure, there is provided a pharmaceutical herbo-mineral-metallic composition comprising Suvarna bhasma in an amount ranging from 3 wt % to 5 wt % of the total weight of the composition, Mouktik bhasma in an amount ranging from 23 wt % to 30 wt % of the total weight of the composition, Guduchi sattva in an amount ranging from 48 wt % to 54 wt % of the total weight of the composition, and at least one edible binder in an amount ranging from 10 wt % to 25 wt % of the total weight of the composition. 
     In exemplary embodiment of the present disclosure, there is provided a pharmaceutical herbo-mineral-metallic composition comprising Suvarna bhasma in an amount of 4 wt % of the total weight of the composition, Mouktik bhasma in an amount of 26 wt % of the total weight of the composition, Guduchi sattva in an amount of 52 wt % of the total weight of the composition and at least one edible gum in an amount of 18 wt % of the total weight of the composition. 
     In accordance with the embodiment of the present disclosure, the Suvarna bhasma is obtained by stabilizing incinerated Suvarna particles having a particle size in the range of 20 nm to 500 nm, with fresh juice of  Ocimum sanctum  leaves. 
     In accordance with the embodiment of the present disclosure, the excipient is selected from the group consisting of gum acacia, guar gum, xanthan gum and other edible gums. 
     The pharmaceutical herbo-mineral-metallic composition is prepared in the form of a solid unit dosages selected from the group consisting of tablet, pill and capsule. 
     The present disclosure further provides a process for preparing the pharmaceutical herbo-mineral metallic composition. The process comprises mixing of Suvarna bhasma, Mouktik bhasma, Guduchi sattva, and at least one excipient to obtain a mixture, wherein the Suvarna bhasma is obtained by stabilizing incinerated Suvarna particles having a particle size in the range of 20 nm to 500 nm with fresh juice of  Ocimum sanctum  leaves (black Tulsi). Water is added to the mixture to obtain dough, followed by pelletizing the dough to obtain pellets. The pellets are dried to obtain dried pellets. The dried pellets are grinded to obtain granules. The so obtained granules are compressed to obtain the pharmaceutical herbo-mineral metallic composition. 
     The Suvarna bhasma is prepared by the process comprising amalgamation of Suvarna with metallic mercury and sulphur powder to obtain amalgamated Suvarna, followed by incinerating the amalgamated Suvarna at a temperature in the range of 650° C. to 700° C. to obtain incinerated Suvarna. The incinerated Suvarna is stabilized by triturating with fresh juice of  Ocimum sanctum  leaves to obtain triturated Suvarna. The triturated Suvarna is stabilized by incinerating at a temperature in the range of 550° C. to 650° C. to obtain Suvarna bhasma having particle size in the range of 20 to 500 nm. 
     The present disclosure also discloses a process for the preparation of Mouktik bhasma and Guduchi sattva. 
     The Mouktik bhasma is prepared by the process which comprises purification of Mouktik (pearl) in butter milk having Mouktik to buttermilk ratio of 1:4 (w/v) and buttermilk having curd to water ratio of 1:2 (w/v) and pH in the range of 3 to 4 to obtain purified Mouktik. The purified Mouktik is triturated with Rose water having ratio of Mouktik to rose water as 1:0.5 (w/v), followed by incinerating at 700° C. to 750° C. to obtain Mouktik bhasma. 
     The Guduchi sattva is prepared by the process which comprises macerating previously pounded and soaked stem pieces of Tinospora species in water having Guduchi to water ratio as 1:4 (w/v), followed by filtration to obtain a filtrate. The filtrate is set aside for a period of 6 hours to 15 hours or is centrifuged to obtain supernatant and smooth starchy sediment of Tinospora. The supernatant is separated to obtain smooth starchy sediment of Tinospora which is dried at a temperature in the range of 40° C. to 45° C. to obtain the Guduchi sattva. 
    
    
     
       BRIEF DESCRIPTION OF THE ACCOMPANYING DRAWING 
       The present disclosure will now be described with the help of the accompanying drawing, in which: 
         FIG. 1A  depicts a graphical representation of Hemoglobin before and after the pharmaceutical herbo-mineral metallic composition treatment in cancer patients; 
         FIG. 1B  depicts a graphical representation of WBC count before and after the pharmaceutical herbo-mineral metallic composition treatment in cancer patients; 
         FIG. 1C  depicts a graphical representation of Platelet count before and after the pharmaceutical herbo-mineral metallic composition treatment in cancer patients; 
         FIG. 1D  depicts a graphical representation of Serum bilirubin before and after the pharmaceutical herbo-mineral metallic composition treatment in cancer patients; 
         FIG. 1E  depicts a graphical representation of SGOT before and after the pharmaceutical herbo-mineral metallic composition treatment in cancer patients; 
         FIG. 1F  depicts a graphical representation of SGPT before and after the pharmaceutical herbo-mineral metallic composition treatment in cancer patients; 
         FIG. 1G  depicts a graphical representation of serum alkaline phosphatase before and after the pharmaceutical herbo-mineral metallic composition treatment in cancer patients; 
         FIG. 1H  depicts a graphical representation of serum creatinine before and after the pharmaceutical herbo-mineral metallic composition treatment in cancer patients; 
         FIG. 2A  depicts a graphical representation of Karnofsky score before and after the pharmaceutical herbo-mineral metallic composition treatment in cancer patients; 
         FIG. 2B  depicts a graphical representation of weight before and after the pharmaceutical herbo-mineral metallic composition treatment in cancer patients; 
         FIG. 2C  depicts a graphical representation of QLQ-Functional score before and after the pharmaceutical herbo-mineral metallic composition treatment in cancer patients; 
         FIG. 2D  depicts a graphical representation of QLQ-Symptom score before and after the pharmaceutical herbo-mineral metallic composition treatment in cancer patients; 
         FIG. 2E  depicts a graphical representation of QLQ-Global score before and after the pharmaceutical herbo-mineral metallic composition treatment in cancer patients; and 
         FIG. 3  depicts a graphical representation of survival pattern of patients in different stages of cancer treated with the pharmaceutical herbo-mineral metallic composition in three groups as per period of treatment. 
     
    
    
     DETAILED DESCRIPTION 
     Embodiments of the present disclosure will now be described with reference to the accompanying drawings. 
     Embodiments are provided so as to thoroughly and fully convey the scope of the present disclosure to the person skilled in the art. Numerous details are set forth, relating to specific components, and methods, to provide a complete understanding of embodiments of the present disclosure. It will be apparent to the person skilled in the art that the details provided in the embodiments should not be construed to limit the scope of the present disclosure. In some embodiments, well-known processes, well-known apparatus structures, and well-known techniques are not described in detail. 
     The terminology used, in the present disclosure, is only for the purpose of explaining a particular embodiment and such terminology shall not be considered to limit the scope of the present disclosure. As used in the present disclosure, the forms “a,” “an,” and “the” may be intended to include the plural forms as well, unless the context clearly suggests otherwise. The terms “comprises,” “comprising,” “including,” and “having,” are open ended transitional phrases and therefore specify the presence of stated features, integers, steps, operations, elements, modules, units and/or components, but do not forbid the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof. The particular order of steps disclosed in the method and process of the present disclosure is not to be construed as necessarily requiring their performance as described or illustrated. It is also to be understood that additional or alternative steps may be employed. 
     The incidence of cancer is increasing worldwide. Although radiotherapy takes care of primary lesion as a site-directed therapy, chemotherapy is used to reduce the primary tumor load as well as distant metastasis. These modalities of treatment are unavoidable lines of treatment for cancer patients, and the adverse side effects of these modalities sometimes interfere with continuation of the treatment. These destructive effects result in impairment of quality of life of patients. 
     It is an accepted fact that in large number of cancer patients, the conventional therapy of radiation and chemotherapy are very often unable to control recurrence or metastasis of cancer. This also results in impairment in Quality of Life of a patient throughout his life-span. 
     Because of the recurrence of cancer and/or spread of the disease all over the body, the conventional modality of treatment as well as surgery no more remain choice of treatment causing death of patients. This is an acute problem in cancer causing low survival period with metastasis/recurrence (Overall Survival-OS) or without metastasis/recurrence (Disease Free Survival-DFS). 
     Therefore, the present disclosure provides a pharmaceutical herbo-mineral-metallic composition well tolerated by patients that mitigates the aforestated problems such as hampered Quality of Life and survival. 
     In an aspect of the present disclosure, there is provided a pharmaceutical herbo-mineral-metallic composition that improves and maintains quality of life of cancer patients by alleviating adverse effects due to chemotherapy and radiotherapy. 
     The pharmaceutical herbo-mineral metallic composition comprises Suvarna bhasma in an amount ranging from 2 wt % to 7 wt % of the total weight of the composition, Mouktik bhasma in an amount ranging from 20 wt % to 35 wt % of the total weight of the composition, Guduchi sattva in an amount ranging from 45 wt % to 60 wt % of the total weight of the composition, and at least one excipient in an amount ranging from 5 wt % to 30 wt % of the total weight of the composition. 
     In an embodiment of the present disclosure, there is provided a pharmaceutical herbo-mineral-metallic composition comprising Suvarna bhasma in an amount ranging from 3 wt % to 5 wt % of the total weight of the composition, Mouktik bhasma in an amount ranging from 23 wt % to 30 wt % of the total weight of the composition, Guduchi sattva in an amount ranging from 48 wt % to 54 wt % of the total weight of the composition, and at least one edible binder in an amount ranging from 10 wt % to 25 wt % of the total weight of the composition. 
     In an exemplary embodiment of the present disclosure, there is provided a pharmaceutical herbo-mineral-metallic composition. The pharmaceutical herbo-mineral-metallic composition comprises Suvarna bhasma in an amount of 4 wt % of the total weight of the composition, Mouktik bhasma in an amount of 26 wt % of the total weight of the composition, Guduchi sattva in an amount of 52 wt % of the total weight of the composition and at least one edible gum in an amount of 18 wt % of the total weight of the composition. 
     Suvarna bhasma is known as incinerated gold and Mouktik bhasma is known as incinerated pearl. The amount of the Suvarna Bhasma below 2 wt % will be sub-therapeutic and in quantities greater than 7 wt %, there will be an overload of the Suvarna Bhasma which will be excreted. Similarly, the lower and upper weight percentages of the other ingredients i.e. Mouktik Bhasma and Guduchi Sattva have been titrated in this formulation keeping the above principle in mind. Ideally, after experimentation it is found that for optimum effect of SBD the composition should contain 4 wt % Suvarna Bhasma, 26 wt % Mouktik Bhasma and 52 wt % Guduchi Sattva which are bound together with a natural gum such as gum acacia to the extent of 18 wt c/o. The ingredients in powder form are blended together. The natural gum is added to the powder blend to form dough with purified water. Pellets are formed from this dough having average weight of 5 gm each. These pellets are tray dried typically at temperature in the range of 40-45° C. The dried pellets are granulated in a mixer grinder and the dry granules are taken for compression tableting. The average weight of the uncoated tablet is 240 mg±5%. The typical shelf life of these tablets is 3 years. 
     The process of preparation of each component also represents modifications in the process to achieve the desired effects. The immunomodulatory effect, the anti-inflammatory and anti-oxidant activities are additional known common features of all the three components. The pharmaceutical herbo-mineral-metallic composition thus selected and processed has the combined effect of minimizing toxicities of conventional therapy, improving Quality of Life throughout the life span, especially in case of debility caused by the disease process and the conventional therapy. The composition is also beneficial in increasing OS and DFS in cancer patients. 
     The rationale for selecting the individual components is as follows: 
     Suvarna bhasma provides proper nourishment to tissues and imparts immunomodulatory action at cellular level. 
     Mouktik Bhasma imparts cooling effect on tissues and promotes proper nourishment of tissues, and reduces inflammation. 
     Guduchi sattva obtained from Tinospora plant promotes digestive power, eliminates undigested material and facilitates metabolism. Its action is mainly exhibited by improving gross digestion besides being an immunomodulator. 
     The pharmaceutical herbo-mineral-metallic composition prepared in accordance with the present disclosure has been found to have the following effects in managing the adverse side effects of chemotherapy. The pharmaceutical herbo-mineral-metallic composition provides nourishment to tissues which is hampered due to conventional systemic anti-cancer therapies. These anti-cancer therapies interfere with normal functions of GI system, produce inflammation in GI system and interfere with the process of absorption of micro nutrients at cellular level. These malfunctions are effectively corrected by the pharmaceutical herbo-mineral-metallic composition. The quantities of Suvarna bhasma, Mouktik bhasma and Guduchi sattva are carefully titrated. Although potency and duration of effectiveness of Suvarna bhasma is satisfactory, the addition of Mouktik bhasma and Guduchi sattva are needed for its easy absorption. In addition, combining Suvarna bhasma with Mouktik bhasma and Guduchi sattva pacifies the aggressiveness of Suvarna Bhasma capacity on the digestive power of the patient as well as absorption at cell and tissue level. Mouktik Bhasma has an antacid effect whereas Guduchi sattva is anti-pyretic and immunomodulator. 
     Suvarna bhasma is known as incinerated gold and Mouktik bhasma is known as incinerated pearl. 
     In accordance with the embodiment of the present disclosure, the Suvarna bhasma is obtained by stabilizing incinerated Suvarna with fresh juice of the leaves of  Ocimum sanctum.    
       Ocimum sanctum , commonly known as holy basil, Tulsi (sometimes spelled thulasi) or tulsi, is an aromatic perennial plant in the family Lamiaceae. It is native to the Indian subcontinent and widespread as a cultivated plant throughout the tropical Southeast Asia.  Ocimum sanctum  is obtained from Bharatiya Sanskriti Darshan Trust (BSDT), Wagholi, Pune. 
     The Tinospora plant is selected from  Tinospora cordifolia, Tinospora sinensis, Tinospora crispa  and  Tinospora glabra.    
       Tinospora cordifolia , which is known by the common names heart-leaved moonseed, Guduchi, and giloy, is an herbaceous vine of the family Menispermaceae indigenous to the tropical areas of India, Myanmar, and Sri Lanka.  Tinospora cordifolia  is obtained from Bharatiya Sanskriti Darshan Trust (BSDT), Wagholi, Pune. 
       Tinospora sinensis  is an herbaceous vine of the family Menispermaceae indigenous to the tropical areas of India, Myanmar and Sri Lanka.  Tinospora sinensis  is collected from Bharatiya Sanskriti Darshan Trust (BSDT), Wagholi, Pune. 
     In accordance with the embodiment of the present disclosure, the excipient is selected from the group consisting of gum acacia, guar gum, xanthan gum and other edible gums. 
     Gum acacia, also known as arabic gum, is a natural gum consisting of the hardened sap of various species of the Acacia tree. Originally, gum acacia was collected from  Acacia nilotica  which was called the “gum arabic tree”. It is harvested commercially from wild trees, mostly in Sudan (80%) and throughout the Sahel, from Senegal to Somalia—though it is historically cultivated in Arabia and West Asia. Gum acacia is collected from Bharatiya Sanskriti Darshan Trust (BSDT), Wagholi, Pune. 
     The pharmaceutical herbo-mineral-metallic composition is prepared in the form of a solid unit dosages selected from the group consisting of tablet, pill and capsule. 
     The pharmaceutical herbo-mineral-metallic composition is administered at a dose of 800 mg to 1000 mg per day by oral administration. 
     The pharmaceutical herbo-mineral-metallic composition of the present disclosure takes care of the short term adverse side-effects in the early period of treatment. The eventual recurrence of cancer and the distant metastasis appear to be controlled by long term use of the pharmaceutical herbo-mineral-metallic composition of the present disclosure. The long term treatment has further helped in maintaining the Quality of Life of patients throughout their lifespan. The long term survival is linked with longer periods of treatment with the pharmaceutical herbo-mineral-metallic composition of the present disclosure. 
     In accordance with another embodiment of the present disclosure, there is provided a process for preparing the pharmaceutical herbo-mineral-metallic composition of the present disclosure. The process comprises mixing of Suvarna bhasma, Mouktik bhasma, Guduchi sattva, and at least one excipient to obtain a mixture, wherein the Suvarna bhasma is obtained by stabilizing incinerated Suvarna with fresh juice of the leaves of  Ocimum sanctum  (black Tulsi). Water is added to the mixture to obtain dough, followed by pelletizing to obtain pellets. The pellets are dried to obtain dried pellets. The dried pellets are grinded to obtain granules. The so obtained granules are compressed to obtain the pharmaceutical herbo-mineral-metallic composition of the present disclosure. 
     The Suvarna bhasma is prepared by the process which comprises amalgamation of Suvarna with metallic mercury and sulphur powder, followed by incinerating amalgamated Suvarna at a temperature in the range of 650° C. to 700° C. to obtain incinerated Suvarna. The incinerated Suvarna is stabilized by triturating with fresh juice of the leaves of  Ocimum sanctum  to obtain stabilized Suvarna. For stabilization Suvarna is incinerated at a temperature in the range of 550° C. to 650° C. to obtain Suvarna bhasma having particle size in the range of 20 to 500 nm. 
     Gold with mercury forms amalgam as an alloy of mercury which is formed through metallic bonding, with electrostatic attractive force. When sulphur is added it forms black sulphide of mercury. During incineration sulphur melts at 114° C., black sulphide of mercury melts at 130° C. and mercury with sulphur sublimes at 650° C. Sulphide atmosphere under pressure and temperature increases solubility of gold which helps reduce particle size of gold and eliminate mercury from the amalgam in the form of sublimates. 
     The Mouktik bhasma is prepared by the process which comprises purification of Mouktik (pearl) in butter milk having Mouktik to buttermilk ratio of 1:4 (w/v) and buttermilk having curd to water ratio of 1:2 (w/v) and pH in the range of 3 to 4 to obtain purified Mouktik. The purified Mouktik is triturated with Rose water having Mouktik to rose water ratio as 1:0.5 (w/v), followed by incinerating at 700° C. to 750° C. to obtain Mouktik bhasma. 
     The Guduchi sattva is prepared by the process which comprises macerating stem pieces of Guduchi in water having Guduchi to water ratio as 1:4 (w/v), followed by filtration to obtain a filtrate. The so obtained filtrate is set aside for a period of time in the range of 6 hours to 15 hours or is optionally centrifuged to obtain supernatant and smooth starchy sediment of Guduchi. The supernatant is separated from the mixture to obtain smooth starchy sediment of Tinospora and the smooth starchy sediment is dried at a temperature in the range of 40° C. to 45° C. to obtain the Guduchi sattva. 
     The  Tinospora  plant is selected from  Tinospora cordifolia, Tinospora sinensis, Tinospora crispa  and  Tinospora glabra.    
     The foregoing description of the embodiments has been provided for purposes of illustration and not intended to limit the scope of the present disclosure. Individual components of a particular embodiment are generally not limited to that particular embodiment, but, are interchangeable. Such variations are not to be regarded as a departure from the present disclosure, and all such modifications are considered to be within the scope of the present disclosure. 
     The present disclosure is further described in the light of following experiments which are set forth for illustration purpose only and not to be construed for limiting the scope of the disclosure. The following experiments can be scaled up to industrial/commercial scale and the results obtained can be extrapolated to industrial scale. 
     EXPERIMENTAL DETAIL 
     Example 1: Composition of the Pharmaceutical Herbo-Mineral-Metallic Composition (in the Form of Tablet) in Accordance with the Present Disclosure 
     The pharmaceutical herbo-mineral-metallic composition was prepared using the following ingredients as given in Table-1. 
     
       
         
           
               
             
               
                 TABLE 1 
               
             
            
               
                   
               
               
                 Pharmaceutical herbo-mineral-metallic composition 
               
            
           
           
               
               
               
               
            
               
                 Sr. 
                   
                 Latin name/ 
                 Quantity for 
               
               
                 No. 
                 Contents 
                 English Name 
                 5 kg batch 
               
               
                   
               
            
           
           
               
               
               
               
               
            
               
                 1 
                 Suvarna Bhasma 
                 Incinerated Gold 
                 210.97 
                 g 
               
               
                 2 
                 Mouktik Bhasma 
                 Incinerated Pearl 
                 1318.56 
                 g 
               
               
                 3 
                 Extract of  Tinospora   
                 Starch of  Tinospora   
                 2637.1 
                 g 
               
               
                   
                 
                   cordifolia 
                 
                 
                   cordifolia 
                 
                   
                   
               
               
                 4 
                 Gum Acacia powder 
                 Binder 
                 833.33 
                 g 
               
               
                   
               
            
           
         
       
     
     Experiment 1: Preparation of Suvarna Bhasma 
     Initially 300 gm of Suvarna foils was amalgamated with 2500 gm of metallic mercury and 2500 gm of sulphur powder having particle size 150 microns and then incinerated 18 times each at 650° C. for 6 hours to get incinerated Suvarna. For stabilization, the incinerated Suvarna was triturated for 6 hours with fresh juice of the leaves of  Ocimum sanctum  (Tulsi) and further incinerated at 600° C. for 5 hours. This incineration process in Tulsi juice was repeated 25 times to obtain Suvarna Bhasma having particle size in the range of 20-500 nm (average particle size_350_nm) when analysed by particle size analyser (90 plus from Brookhaven Instruments, USA). 
     Result: Specification of Suvarna bhasma
 
Description—Brown coloured, very fine free flowing powder
 
     Loss on Drying—NMT 0.5% w/w 
     Loss on Ignition—NMT 1% w/w 
     Acid insoluble ash—90 to 98% w/w 
     Assay as Au—NLT 85% w/w 
     Experiment 2: Preparation of Mouktik Bhasma 
     8 Kg Mouktik (pearl) was boiled in 32 L of butter milk having curd to water ratio of 1:2 w/v and pH of 3, to obtain purified Mouktik. The so obtained purified Mouktik was powdered and triturated with 4 L of rose water to obtain triturated powder. The triturated powder was then incinerated using cow-dung cakes at 700° C. to obtain Mouktik Bhasma (incinerated pearl). 
     Result: Specification of Mouktik bhasma:
 
Description: Greyish white coloured, very fine powder
 
     Loss on Drying—NMT 0.5% w/w 
     Acid insoluble ash—NMT 2% w/w
 
Calcium assay—38 to 40% w/w
 
pH—10 to 11
 
     Experiment 3: Extraction of Starch from  Tinospora cordifolia/sinenses    
     50 Kg of Fresh stems of  Tinospora cordifolia  were chopped into small pieces. These pieces were crushed and then soaked for 12 hours in 4 times (w/v) of potable water (200 L) in a stainless steel vessel. The mixture was macerated in water thoroughly and filtered slowly to obtain solution containing aqueous extract of  Tinospora cordifolia . The solution thus obtained was kept aside for 12 hours to obtain supernatant and smooth starchy sediment of  Tinospora cordifolia . The supernatant was carefully separated to obtain smooth starchy sediment. The smooth starchy sediment of  Tinospora cordifolia  was evaporated in an oven at 45° C. to obtain Guduchi Sattva in the form of dry starch. 
     Result: Specification of starch extract of  Tinospora cordifolia/sinensis  
 
Description: White or greyish white coloured very fine free flowing starchy powder
 
     Loss on Drying—NMT 5% w/w 
     Acid insoluble ash—NMT 1% w/w
 
Gelation temperature—60 to 75° C.
 
     Experiment 4: Preparation of the Pharmaceutical Herbo-Mineral-Metallic Composition 
     The pharmaceutical herbo-mineral-metallic composition was prepared in three batches as per details given in Table 2 
     
       
         
           
               
             
               
                 TABLE 2 
               
             
            
               
                   
               
               
                 Pharmaceutical herbo-mineral-metallic composition in three batches 
               
            
           
           
               
               
               
               
               
               
            
               
                 Sr. 
                   
                 Latin name/ 
                 Quantity for 
                 Quantity for 
                 Quantity for 
               
               
                 No. 
                 Contents 
                 English Name 
                 5 kg batch 1 
                 5 kg batch 2 
                 5 kg batch 3 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
               
               
            
               
                 1 
                 Suvarna Bhasma 
                 Incinerated Gold 
                 210.97 
                 g 
                 110 
                 g 
                 350 
                 g 
               
               
                 2 
                 Mouktik Bhasma 
                 Incinerated Pearl 
                 1318.56 
                 g 
                 1700 
                 g 
                 1000 
                 g 
               
               
                 3 
                 Extract of 
                 Starch of  Tinospora   
                 2637.1 
                 g 
                 2940 
                 g 
                 2250 
                 g 
               
               
                   
                 
                   Tinospora 
                   cordifolia 
                 
                 
                   cordifolia 
                 
                   
                   
                   
                   
                   
                   
               
               
                 4 
                 Gum Acacia 
                 Binder 
                 833.33 
                 g 
                 250 
                 g 
                 1400 
                 g 
               
               
                   
                 powder 
               
               
                   
               
            
           
         
       
     
     In a mixer, 210.97_gm of Suvarna bhasma, 1318.56_gm of Mouktik bhasma, 2637.1 gm of Guduchi Sattva (starch from  Tinospora cordifolia ) and 833.33 gm of gum acacia were mixed to obtain a mixture. The amounts are given in Table 1. To this mixture, 3 L of water was added to obtain dough. The dough was further pelletized to obtain pellets. The so obtained pellets were dried in oven at 45° C. to obtain dried pellets. The dried pellets were grinded to obtain granules having powder to granule ratio of 30:70. The so obtained granules were compressed in a tablet punching machine to obtain compressed tablet of weight 237 mg±5% each. 
     Results: Specifications of the pharmaceutical herbo-mineral-metallic composition
 
Appearance: Grey colour, round
 
Shape: Biconvex tablets
 
Weight variation: 0.2250 to 0.2500 g
 
Average weight: 237±12 mg
 
     Hardness: 1-2 Kg/cm 2    
     Friability: NMT 1% w/w 
     Disintegration Time: NMT 30 min 
     Diameter: 7 to 7.5 mm 
     Width: 3.3 to 4.6 mm 
     Acute toxicity: LD 50&gt;2000 mg/kg 
     Experiment 5: Elemental Analysis of the Pharmaceutical Herbo-Mineral-Metallic Composition 
     The below mentioned studies have been conducted for the pharmaceutical herbo-mineral-metallic composition of batch 1. 
     The pharmaceutical herbo-mineral-metallic composition was tested for elemental assay for gold (Au) and calcium (Ca) (Table 3) and for heavy metal analysis of mercury (Hg), lead (Pb), cadmium (Cd) and arsenic (As) (Table 4). 
     Results: 
       
     
       
         
           
               
             
               
                 TABLE 3 
               
             
            
               
                   
               
               
                 Elemental assay for gold and calcium in the pharmaceutical  
               
               
                 herbo-mineral-metallic composition 
               
            
           
           
               
               
               
               
               
               
            
               
                 Name of 
                 Mean of 3 
                 Max. Dose per 
                   
                   
                 Permissible 
               
               
                 element 
                 samples 
                 day in mg 
                 SD 
                 p Value 
                 limit per day 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
            
               
                 Gold 
                 2.64% 
                 20.82 
                 0.09 
                 0.0004 
                 100  
                 mg 
               
               
                 Calcium 
                 13.1% 
                 103.49 
                 0.12 
                 &lt;0.0001 
                 1000-1200  
                 mg 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 4 
               
             
            
               
                   
               
               
                 Heavy metals analysis of the pharmaceutical herbo-mineral-metallic 
               
               
                 composition 
               
            
           
           
               
               
               
               
               
               
            
               
                 Name of 
                 Mean of 3 
                 Max. Dose per 
                   
                   
                 Permissible 
               
               
                 element 
                 samples 
                 day in ppm 
                 SD 
                 p Value 
                 limit per day 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
               
            
               
                 Cadmium 
                 1.28 
                 ppm 
                 1.28 
                 0.23 
                 0.01 
                 &lt;3  
                 ppm 
               
               
                 Mercury 
                 0.83 
                 ppm 
                 0.83 
                 0.0005 
                 &lt;0.0001 
                 &lt;1  
                 ppm 
               
               
                 Lead 
                 17.02 
                 ppm 
                 17.02 
                 0.01 
                 &lt;0.0001 
                 &lt;20 
                 ppm 
               
            
           
           
               
               
               
               
               
               
               
            
               
                 Arsenic 
                 Nil 
                 Nil 
                 — 
                 — 
                 &lt;0.3 
                 ppm 
               
               
                   
               
            
           
         
       
     
     From Tables 3 and 4, it is evident that gold and calcium content and heavy metal content of the pharmaceutical herbo-mineral-metallic composition were within permissible limits. 
     Experiment 6: Toxicity Studies of the Pharmaceutical Herbo-Mineral-Metallic Composition 
     The pharmaceutical herbo-mineral-metallic composition was also tested for acute and chronic toxicity studies on rats (Animal toxicity studies were conducted at ACTREC, Tata Memorial Centre, Navi Mumbai). 
     Acute Toxicity Study of the Pharmaceutical Herbo-Mineral-Metallic Composition— 
     Acute toxicity study of the pharmaceutical herbo-mineral-metallic composition was conducted for 2000 mg/kg single dose for 14 days in Sprague Dawley rats. One of the contents of the pharmaceutical herbo-mineral-metallic composition was Suvarna Bhasma (2.64% of Gold) and its daily dose was 41.64 mg. The pharmaceutical herbo-mineral-metallic composition of the present disclosure showed all the biochemical and haematological parameters within normal limits at the end of the experiment as shown in table 5. 
     
       
         
           
               
             
               
                 TABLE 5 
               
             
            
               
                   
               
               
                 Acute toxicity studies of the pharmaceutical herbo-mineral- 
               
               
                 metallic composition: Biochemical and hematological analysis 
               
            
           
           
               
               
               
               
            
               
                   
                   
                 Vehicle (Cow&#39;s ghee) 
                 The pharmaceutical herbo- 
               
               
                   
                 Normal control 
                 control 
                 mineral-metallic composition 
               
               
                   
                 (n = 4) 
                 (n = 10) 
                 (n = 10) 
               
            
           
           
               
               
               
               
               
               
               
            
               
                 Parameters 
                 0 day 
                 14 day 
                 0 day 
                 14 day 
                 0 day 
                 14 day 
               
               
                   
               
            
           
           
               
            
               
                 Biochemical parameters (mean ± sd) 
               
            
           
           
               
               
               
               
               
               
               
            
               
                 BUN 
                 27.75 ± 2.66 
                 27.75 ± 2.66 
                 25.45 ± 1.47 
                 36.50 ± 1.22  
                 33.41 ± 2.49 
                 12.66 ± 5.16 
               
               
                 Sr. creatinine 
                  0.42 ± 0.06 
                  0.42 ± 0.06 
                  0.50 ± 0.03 
                 0.57 ± 0.01 
                  0.30 ± 0.03 
                  0.34 ± 0.09 
               
               
                 Bilirubin 
                  0.13 ± 0.03 
                  0.13 ± 0.03 
                  0.11 ± 0.02 
                 0.25 ± 0.13 
                  0.07 ± 0.02 
                  0.22 ± 0.01 
               
               
                 SGOT 
                 108.75 ± 7.83  
                 108.75 ± 7.83  
                 208.70 ± 32.40 
                 146.50 ± 9.78  
                 218.30 ± 13.80 
                 166.10 ± 6.48  
               
               
                 SGPT 
                 64.75 ± 7.49 
                 64.75 ± 7.49 
                  79.90 ± 11.68 
                 73.30 ± 10.22 
                 71.60 ± 7.70 
                 51.10 ± 4.99 
               
               
                 Alkaline Phosphate 
                 395.00 ± 44.22 
                 395.00 ± 44.22 
                 396.60 ± 21.66 
                 325.40 ± 22.07  
                 398.80 ± 16.27 
                 334.00 ± 25.53 
               
            
           
           
               
            
               
                 Haematological parameters (mean ± sd) 
               
            
           
           
               
               
               
               
               
               
               
            
               
                 WBC 
                  7.76 ± 0.45 
                  7.76 ± 0.45 
                  6.67 ± 0.51 
                 5.68 ± 0.58 
                  4.76 ± 0.21 
                  8.08 ± 0.38 
               
               
                 RBC 
                  7.34 ± 0.19 
                  7.34 ± 0.19 
                  7.56 ± 0.12 
                 7.68 ± 0.09 
                  7.89 ± 0.01 
                  7.19 ± 0.30 
               
               
                 Hb 
                 13.90 ± 0.16 
                 13.90 ± 0.16 
                 14.13 ± 0.18 
                 14.08 ± 0.33  
                 14.18 ± 0.19 
                 14.13 ± 0.06 
               
               
                 Platelets 
                 876.00 ± 48.63 
                 876.00 ± 48.63 
                 788.90 ± 44.55 
                 913.10 ± 51.30  
                 709.00 ± 28.12 
                 753.30 ± 25.52 
               
               
                 Neutrophils 
                  5.15 ± 0.59 
                  5.15 ± 0.59 
                  3.74 ± 0.99 
                 3.75 ± 0.57 
                  3.53 ± 1.17 
                  1.74 ± 0.47 
               
               
                 Lymphocytes 
                 83.65 ± 1.54 
                 83.65 ± 1.54 
                 79.09 ± 2.96 
                 81.59 ± 2.37  
                 73.60 ± 1.17 
                 83.45 ± 1.39 
               
               
                   
               
            
           
         
       
     
     It was observed that the administration of a single large dose (2000 mg/kg body weight) of the pharmaceutical herbo-mineral-metallic composition did not show change in behavioral pattern in treated and control rats. 
     From table 5, it is evident that there was no clinically significant change in various hematological and biochemical parameters. 
     There was no significant change observed when histopathology of different organs from animals treated with the pharmaceutical herbo-mineral-metallic composition was compared with animals belonging to normal control and vehicle control groups. Thus, from above results, it is concluded that a single large dose of the pharmaceutical herbo-mineral-metallic composition and vehicle (clarified butter or cow&#39;s ghee) were well tolerated by the animals without adverse effects. 
     Chronic Toxicity Study of the Pharmaceutical Herbo-Mineral-Metallic Composition: 
     Chronic toxicity study of the pharmaceutical herbo-mineral-metallic composition was conducted for 30 days in Sprague Dawley rats with therapeutic dose (×), and (5×) and (10×) doses. One of the contents of the pharmaceutical herbo-mineral-metallic composition was Suvarna Bhasma (2.64% of Gold) and its daily dose was 41.64 mg. The pharmaceutical herbo-mineral-metallic composition of the present disclosure showed all the biochemical and haematological parameters within normal range as shown in table 6. 
     
       
         
           
               
             
               
                 TABLE 6 
               
             
            
               
                   
               
               
                 Chronic toxicity studies of the pharmaceutical herbo-mineral- 
               
               
                 metallic composition: Biochemical and hematological analysis. 
               
            
           
           
               
               
               
               
            
               
                   
                 X dose 
                 5X dose 
                 10 X dose 
               
            
           
           
               
               
               
               
               
               
               
            
               
                 Parameter 
                 0 day 
                 30 day 
                 0 day 
                 30 day 
                 0 day 
                 30 day 
               
               
                   
               
            
           
           
               
            
               
                 Biochemical parameters (mean ± sd) 
               
            
           
           
               
               
               
               
               
               
               
            
               
                 BUN 
                 28.70 ± 1.51 
                 29.45 ± 2.15 
                 35.7 ± 0.87 
                 36.17 ± 2.02  
                 38.45 ± 2.08  
                 32.63 ± 2.90  
               
               
                 Sr. creat. 
                  0.67 ± 0.19 
                  0.77 ± 0.14 
                 0.40 ± 0.03 
                  0.42 ± 0.035 
                 0.37 ± 0.02 
                 0.38 ± 0.03 
               
               
                 Bilirubin 
                  0.16 ± 0.03 
                  0.24 ± 0.04 
                 0.17 ± 0.02 
                 0.21 ± 0.03 
                 0.14 ± 0.03 
                 0.15 ± 0.02 
               
               
                 SGPT 
                 66.00 ± 3.13 
                 39.33 ± 4.41 
                 36.67 ± 3.07  
                 28.50 ± 2.31  
                 40.83 ± 1.92  
                 28.33 ± 4.64  
               
               
                 SGOT 
                 285.7 ± 45.8 
                 265.2 ± 39.4 
                 166.7 ± 9.4  
                 162.3 ± 9.0  
                 160.5 ± 9.1  
                 145.7 ± 14.3  
               
               
                 Alkaline phosphatase 
                 268.00 ± 13.2  
                 257.00 ± 17.7  
                  149 ± 15.7 
                 116.5 ± 14.5  
                 195.17 ± 14.3  
                 106.2 ± 6.2  
               
            
           
           
               
            
               
                 Haematological parameters (mean ± sd) 
               
            
           
           
               
               
               
               
               
               
               
            
               
                 HB 
                 14.850 ± 0.14  
                 14.42 ± 0.16 
                 15.72 ± 0.39  
                 16.2 ± 0.26 
                 16.0 ± 0.40 
                 16.27 ± 0.27  
               
               
                 WBC 
                 6.150 ± 0.5  
                  4.5 ± 0.85 
                 7.55 ± 0.70 
                 8.82 ± 0.47 
                  7.2 ± 0.66 
                 7.51 ± 0.70 
               
               
                 RBC 
                 8.433 ± 0.07 
                  7.8 ± 0.07 
                 9.11 ± 0.24 
                  8.9 ± 0.13 
                  9.1 ± 0.23 
                 9.20 ± 0.20 
               
               
                 Platelets 
                 833.50 ± 108.4 
                 644.7 ± 56.2 
                 760.5 ± 20.57 
                 813.7 ± 42.16 
                 742.2 ± 14.11 
                 703.2 ± 52.7  
               
               
                 Neutrophils 
                 9.367 ± 3.0  
                  4.0 ± 1.5 
                  7.2 ± 0.98 
                  5.6 ± 1.26 
                  3.4 ± 0.29 
                  8.3 ± 1.82 
               
               
                 Lymphocytes 
                 63.850 ± 3.9  
                 71.1 ± 1.6 
                 64.08 ± 4.32  
                 72.9 ± 3.72 
                 64.4 ± 0.10 
                 63.9 ± 6.33 
               
               
                 Monocytes 
                 14.72 ± 1.4  
                     12 ± 0.9 
                 13.83 ± 1.9  
                 14.6 ± 2.10 
                 19.23 ± 0.69  
                 15.5 ± 3.98 
               
               
                   
               
            
           
         
       
     
     From table 6, it is evident that daily administration of the pharmaceutical herbo-mineral-metallic composition at therapeutic dose, 5 times and 10 times of therapeutic dose given for 30 days did not produce any hematological and biochemical changes in rats when compared to vehicle control and normal control. Thus, the pharmaceutical herbo-mineral-metallic composition is considered safe for long term use. Further, human equivalent dose of up to 100 mg daily is considered to be safe. 
     Example 2: Efficacy Studies of the Pharmaceutical Herbo-Mineral-Metallic Composition on Various Types of Cancers 
     The therapeutic effectiveness in terms of improving quality of life (QoL); extending overall survival (OS) and disease free survival (DFS) of the pharmaceutical herbo-mineral-metallic composition was assessed on 124 patients. These patients belonged to both genders and age group between 20 to 78 years suffered from various types of cancers at different stages. These patients were recruited before, during or after conventional anti-cancer treatment such as surgery, radiotherapy, chemotherapy and hormonal treatment and were given herbo-mineral-metallic composition of the present disclosure from 1 to 6 years. These patients were categorized based on duration of treatment with the pharmaceutical herbo-mineral-metallic composition, viz treated for 1-2 years (Group 1: 88 patients), 2-4 years (Group 2: 26 patients) and 4-6 years (Group 3: 10 patients). While 2 children of age 3 years suffering from leukemia were recruited and administered half of the adult dose in this study. 
     Experiment 1: Assessment of Biochemical Parameters and Quality of Life of Cancer Patients Treated with the Herbo-Mineral-Metallic Composition from 1 Year and 6 Years 
     The distribution of patients having different types of cancers and the stages of the disease included in the study are given in table 7. 
     Outcome Measures— 
     The assessment criteria for outcome measures include biochemical parameters like haemogram, liver function and kidney function; clinical parameters such as clinical examinations and radiological investigations. For assessment of well-being measures like Karnofsky score, Functional, Global, and Symptom scores of QLQ were used. Karnofsky score and scoring for QLQ are internationally accepted means of scoring symptoms and quality of life for cancer patients used in various studies in clinical trials. Karnofsky score was recorded on 0-100 scale, the score of 100 showing normal performance status. 
     Observations and Results— 
     As given in table 7 the cohort includes 60% breast cancer, 13% oral cavity cancers and remaining 27% other types of cancers. Among these, 14% patients were in stage IV, 45% in stage III, 34% in stage II and 7% in stage I cancer. One brain tumour patient belongs to grade II, one CML patient to accelerated stage, and one AML patient to M4 stage. 
     
       
         
           
               
             
               
                 TABLE 7 
               
             
            
               
                   
               
               
                 Distribution of cancer types and stages of the disease  
               
               
                 in the cohort included in the study 
               
            
           
           
               
               
               
               
            
               
                   
                   
                   
                 Stage-wise distribution of  
               
               
                   
                   
                 Total No. 
                 patients 
               
            
           
           
               
               
               
               
               
               
               
            
               
                 Sr. 
                   
                 of 
                 Stage 
                 Stage 
                 Stage 
                 Stage 
               
               
                 No. 
                 Diagnosis 
                 Patients 
                 I 
                 II 
                 III 
                 IV 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
            
               
                  1 
                 CA Breast 
                 76 
                 2 
                 36 
                 30 
                 8 
               
               
                  2 
                 CA Lung 
                 7 
                 0 
                 1 
                 1 
                 5 
               
               
                  3 
                 CA Ovaries 
                 6 
                 0 
                 1 
                 4 
                 1 
               
               
                  4 
                 CA Buccal Mucosa 
                 5 
                 1 
                 1 
                 0 
                 3 
               
               
                  5 
                 CA Tongue 
                 3 
                 0 
                 0 
                 2 
                 1 
               
               
                  6 
                 Non-Hodgkin&#39;s  
                 3 
                 0 
                 1 
                 2 
                 0 
               
               
                   
                 lymphoma 
                   
                   
                   
                   
                   
               
               
                  7 
                 CA Alveolus 
                 2 
                 0 
                 1 
                 0 
                 1 
               
               
                  8 
                 CA Pharynx 
                 2 
                 0 
                 0 
                 1 
                 1 
               
               
                  9 
                 CA Pyriform fossa 
                 2 
                 0 
                 0 
                 1 
                 1 
               
               
                 10 
                 Hodgkin&#39;s lymphoma 
                 2 
                 0 
                 0 
                 2 
                 0 
               
               
                 11 
                 Myeloid leukemia 
                 2 (1— 
                 NA 
                 NA 
                 NA 
                 NA 
               
               
                   
                   
                 AML/M4, 
                   
                   
                   
                   
               
               
                   
                   
                 1—Ac- 
                   
                   
                   
                   
               
               
                   
                   
                 celerated 
                   
                   
                   
                   
               
               
                   
                   
                 CML) 
                   
                   
                   
                   
               
               
                 12 
                 CA Stomach 
                 1 
                 0 
                 1 
                 0 
                 0 
               
               
                 13 
                 CA Colon 
                 1 
                 0 
                 1 
                 0 
                 0 
               
               
                 14 
                 CA Rectum 
                 1 
                 1 
                 0 
                 0 
                 0 
               
               
                 15 
                 CA Gall bladder 
                 1 
                 0 
                 0 
                 1 
                 0 
               
               
                 16 
                 CA Pancreas 
                 1 
                 0 
                 1 
                 0 
                 0 
               
               
                 17 
                 CA Maxilla 
                 1 
                 0 
                 0 
                 0 
                 1 
               
               
                 18 
                 CA Larynx 
                 1 
                 0 
                 0 
                 0 
                 1 
               
               
                 19 
                 Sarcoma 
                 1 
                 0 
                 0 
                 0 
                 1 
               
               
                 20 
                 CA Cervix 
                 1 
                 0 
                 0 
                 0 
                 1 
               
               
                 21 
                 CA Prostate 
                 1 
                 0 
                 0 
                 0 
                 1 
               
               
                 22 
                 Brain Tumours (Grade) 
                 1 
                 0 
                 1 
                 0 
                 0 
               
               
                 23 
                 Multiple Myeloma 
                 1 
                 1 
                 0 
                 0 
                 0 
               
               
                 24 
                 Lymphatic leukemia 
                 1 
                 NA 
                 NA 
                 NA 
                 NA 
               
               
                 25 
                 Primary Multiple cancer 
                 1 
                 0 
                 1 
                 0 
                 0 
               
               
                   
                 TOTAL 
                 124 
                 5 
                 45 
                 44 
                 26 
               
               
                   
               
               
                 NA—Not Applicable or not defined 
               
            
           
         
       
     
     Biochemical Parameters— 
     Biochemical parameters of 124 cancer patients were studied before and after treatment with the pharmaceutical herbo-mineral-metallic composition of the present disclosure ( FIGS. 1A to 1H ). From  FIGS. 1A to 1H , it is observed that the haemoglobin levels increased while Serum alkaline phosphatase, an indicator of disease progression, showed remarkable decrease after treatment with the pharmaceutical herbo-mineral-metallic composition in patients of all the 3 groups. All other parameters showed a trend towards better outcome and were in normal range throughout the study. 
     Well-being of Patients (Recorded as Karnofsky Score, QoL Scores and Weight): 
     Parameters of well-being were evaluated before and after the treatment with the pharmaceutical herbo-mineral-metallic composition and the results were represented as  FIGS. 2A to 2E . As shown in  FIG. 2A , Karnofsky score was highly significant (p=0.0002) in Group 1 and (p=0.0006) in Group 3 while significant (p=0.03) in Group 2. 
     As per  FIG. 2B , there was no significant change in weight in all the three groups. Thus chemotherapy/radiotherapy induced weight loss was not seen in patients treated with the pharmaceutical herbo-mineral-metallic composition. 
     In this study, it was observed that functional and global scores increased in all the 3 groups of the patients ( FIGS. 2C and 2E ). As shown in  FIG. 2C , the differences were highly or very highly significant respectively in group 1 and 3, while in case of global score group, 1 and 3 showed highly significant and group 2 showed significant difference ( FIG. 2E ), Similarly as depicted in  FIG. 2D  significant or highly significant reduction in symptoms was observed in all three groups of the patients. Notably, a very highly significant reduction in symptoms was observed in group 1 patients during crucial period of 1-2 years, when patients suffered from intermediate and long-term side-effects of chemotherapy and radiotherapy. 
     Based on these results, it is evident that the pharmaceutical herbo-mineral-metallic composition of present disclosure improved well-being and strength of the patients, thus resulting into improving QoL. 
     Experiment 2 
     Survival Pattern of Analysis of 124 Patients Treated with the Pharmaceutical Herbo-Mineral-Metallic Composition of the Present Disclosure (ASBD) Vis-à-Vis Period of Treatment and Period of Survival 
     Survival pattern of patients in terms of Disease Free Survival (DFS) and Overall Survival (OS) was analyzed and given in table 8 and  FIG. 3 . As explained in experiment 1 of example 2, cancer patients were categorized in 3 groups based on duration of treatment with the pharmaceutical herbo-mineral-metallic composition, viz those treated for 1-2 years (Group 1: 88 patients), 2-4 years (Group 2: 26 patients) and 4-6 years (Group 3:10 patients). The life span of patients in DFS or OS status was observed for the period of survival and classified as survival for 1-2 years, 2-3 years, 3-4 years, 4-5 years, 5-10 years, and above 10 years. 
     Results— 
     For ease of interpretation of data in terms of OS and DFS, stage I and II patients were grouped together and stage III and IV patients were combined. It was possible because stage I and II patients have better survival, localized tumours, may differ in size of tumour however the distant metastasis was never seen. Group III and IV patients have larger primary tumours with local recurrence as well as distant metastasis and were difficult to treat. Table 8 represents actual number of patients showing DFS and OS for various time periods. In addition percent survival data has also been included in each case in table 8. 
     
       
         
           
               
             
               
                 TABLE 8 
               
             
            
               
                   
               
               
                 Survival patterns of number and percentage of patients in different stages, treated 
               
               
                 with the pharmaceutical herbo-mineral-metallic composition in 3 groups- 
               
            
           
           
               
               
               
               
            
               
                   
                 No. and % of patients treated for 
                 No. and % of patients treated for 
                 No. and % of patients treated for 
               
               
                   
                 minimum 1 to maximum 2 years* 
                 minimum 2 to maximum 4 years* 
                 minimum 4 to maximum 6 years* 
               
               
                   
                 (Group 1) 
                 (Group 2) 
                 (Group 3) 
               
            
           
           
               
               
            
               
                 Survival 
                 Stage 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
               
               
            
               
                 period 
                 I/II 
                 III/IV 
                 NA** 
                 Total 
                 I/II 
                 III/IV 
                 NA** 
                 Total 
                 I/II 
                 III/IV 
                 NA** 
                 Total 
               
               
                 in years 
                 No/(%) 
                 No/(%) 
                 No/(%) 
                 No/(%) 
                 No/(%) 
                 No/(%) 
                 No/(%) 
                 No/(%) 
                 No/(%) 
                 No/(%) 
                 No/(%) 
                 No/(%) 
               
               
                   
               
               
                 1 to 2 
                 17  
                 25  
                 1 
                 43/88 
                 2 
                 0 
                 0 
                 2/26 
                   
                   
                   
                   
               
               
                   
                 (46)  
                 (51)  
                 (50)  
                 (49) 
                 (20)  
                   
                   
                  (8) 
               
               
                 2 to 3 
                 9 
                 7 
                 1 
                 17/88 
                 0 
                 7 
                 0 
                 7/26 
               
               
                   
                 (24)  
                 (14)  
                 (50)  
                 (19) 
                   
                 (44)  
                   
                 (27) 
               
               
                 3 to 4 
                 3 
                 2 
                 0 
                  5/88 
                 0 
                 1 
                 0 
                 1/26 
               
               
                   
                 (8) 
                 (4) 
                   
                  (6) 
                   
                 (6) 
                   
                  (4) 
               
               
                 4 to 5 
                 1 
                 3 
                 0 
                  4/88 
                 3 
                 2 
                 0 
                 5/26 
                 0 
                 1 
                   
                 1/10 
               
               
                   
                 (3) 
                 (6) 
                   
                  (5) 
                 (30)  
                 (13)  
                   
                 (19) 
                   
                 (20)  
                   
                 (10) 
               
               
                 5 to 10 
                 6 
                 11  
                 0 
                 17/88 
                 4 
                 4 
                 0 
                 8/26 
                 3 
                 4 
                 2 
                 9/10 
               
               
                   
                 (16)  
                 (22)  
                   
                 (19) 
                 (40)  
                 (25)  
                   
                 (31) 
                 (100)  
                 (80)  
                 (100)  
                 (90) 
               
               
                 10 and 
                 1 
                 1 
                 0 
                 2/88 
                 1 
                 2 
                 0 
                 3/26 
                 0 
                 0 
                   
                  0 
               
               
                 above 
                 (3) 
                 (2) 
                   
                 (10 and 
                 (10)  
                 (13)  
                   
                 (11, 12 
               
               
                   
                   
                   
                   
                 18 yrs) 
                   
                   
                   
                 and 19 yrs) 
               
               
                   
                   
                   
                   
                 (2) 
                   
                   
                   
                 (12) 
               
               
                 Total 
                 37  
                 49  
                 2 
                 88 
                 10  
                 16  
                 0 
                 26 
                 3 
                 5 
                 2 
                 10 
               
               
                   
               
               
                 *The pharmaceutical herbo-mineral metallic composition treatment discontinued thereafter 
               
               
                 **Patients with Leukemia and brain tumour are classified using special type of staging and grading respectively hence are mentioned NA. 
               
            
           
         
       
     
     Major percentage (about 75%) of stage I/II patients treated with the pharmaceutical herbo-mineral-metallic composition in group 1 (treated for 1-2 yrs.) survived only up to 3-4 years, whereas if the treatment was given for longer period (Group 2 &amp; 3), the patients survived beyond 5 years. On the other hand, about 50-70% of patients in stage III/IV in group 1 &amp; 2 survived only up to 3-4 years, however those who have taken long term treatment of the pharmaceutical herbo-mineral-metallic composition (Group 3 and also 2) survived up to 10-15 years, although they belonged to difficult-to-treat stage III and IV. This indicates that patients have longer life if treated for longer time with the pharmaceutical herbo-mineral-metallic composition. Also stage III/IV patients who normally have poor survival, showed extended DFS and OS status when the pharmaceutical herbo-mineral-metallic composition treatment was given for longer period. 
     Experiment 3 
     Survival Pattern in Terms of DFS and OS of Patients Survived for More than 4 Years Compared to Clinical Conditions— 
     Amongst 124 patients, 49 patients who have survived for more than 4 years are included in this study for their DFS or OS status and the results are depicted in table 9. 
     Results: 
     Amongst the long survivors, 19 were in stage I/II disease, 28 in stage III/IV disease and 2 patients for whom stage was not specifically defined. 
     In table 9 the status of survival and clinical parameters were analyzed together to assess improvement in clinical condition compared with disease free survival. 
     
       
         
           
               
             
               
                 TABLE 9 
               
             
            
               
                   
               
               
                 Patients treated with the pharmaceutical herbo-mineral-metallic composition 
               
               
                 observed after 4+ years for survival vis-à-vis clinical parameters 
               
            
           
           
               
               
               
               
               
               
               
               
            
               
                   
                 Reduction in 
                 Reduction in 
                 Increase 
                 Increase 
                   
                   
                   
               
               
                   
                 disease related 
                 therapy related 
                 in 
                 in 
                 Radiological 
                 Karnofsky 
                 QoL assessed 
               
               
                   
                 symptoms 
                 adverse effects* 
                 HB 
                 Weight 
                 findings 
                 score 
                 by QLQ C-30 
               
               
                   
                   
               
            
           
           
               
            
               
                 Stage I/II Disease -19 patients 
               
            
           
           
               
               
               
               
               
               
               
               
            
               
                 DFS - 
                 6/15 
                  6/15 
                 5/15 
                 10/15 
                 All disease 
                 Increased in 
                 Improved in 
               
               
                 15/19 
                   
                   
                   
                   
                 free 
                 all 90-100 
                 all 
               
               
                 OS - 
                 3/4  
                 3/4 
                 3/4  
                 3/4 
                 Stable disease 
                 Increased in 
                 Improved in 
               
               
                 4/19 
                   
                   
                   
                   
                 in 3 and 
                 3/4 80-90 
                 all 
               
               
                   
                   
                   
                   
                   
                 progressive 
               
               
                   
                   
                   
                   
                   
                 disease in 1 
               
            
           
           
               
            
               
                 Stage III/IV Disease - 28 patients 
               
            
           
           
               
               
               
               
               
               
               
               
            
               
                 DFS- 
                 1/10 
                  5/10 
                 5/10 
                  7/10 
                 All disease 
                 Increased in 
                 Improved in 
               
               
                 10/28 
                   
                   
                   
                   
                 free 
                 all 90-100 
                 all 
               
               
                 OS- 
                 5/18 
                 11/18 
                 7/18 
                  8/18 
                 7 status quo, 
                 Status quo 
                 Improved in 
               
               
                 18/28 
                   
                   
                   
                   
                 11 increased 
                 score - 
                 patients with 
               
               
                   
                   
                   
                   
                   
                 mets. 
                 80-90, Patients 
                 status quo 
               
               
                   
                   
                   
                   
                   
                   
                 with Increased 
                 disease and 
               
               
                   
                   
                   
                   
                   
                   
                 mets, score 
                 maintained 
               
               
                   
                   
                   
                   
                   
                   
                 around 80 
                 in patients 
               
               
                   
                   
                   
                   
                   
                   
                   
                 with increased 
               
               
                   
                   
                   
                   
                   
                   
                   
                 metastatic 
               
               
                   
                   
                   
                   
                   
                   
                   
                 disease. 
               
            
           
           
               
            
               
                 STAGE not defined - 2 patients 
               
            
           
           
               
               
               
               
               
               
               
               
            
               
                 DFS2/2 
                 2/2  
                 2/2 
                 2/2  
                 2/2 
                 All disease 
                 Increased in 
                 Improved in 
               
               
                   
                   
                   
                   
                   
                 free 
                 all 90-100 
                 all 
               
               
                   
               
               
                 *Adverse effects included nausea, vomiting, fever, fatigue, body ache etc. 
               
            
           
         
       
     
     Out of 19 patients having stage I/II disease, 15 showed disease free survival (DFS) and 4 showed overall survivals with steady status of the disease (OS). The radiological findings showed disease free condition in all DFS patients while 3 OS patients showed stable status of metastatic disease and 1 patient showed progressive metastasis. Both DFS and OS patients showed improvement in Karnofsky score and quality of life. 
     As for the patients in stage III/IV treated with the pharmaceutical herbo-mineral-metallic composition and survived for 4+ years, 10 were in DFS status, while 18 showed OS status. This is an encouraging observation wherein 36% patients were diseases free (DFS) and 64% patients were in OS category, which is otherwise not reported often. Among 18 OS patients, 7 patients showed radiologically stable disease condition with good QoL and 11 patients showed progressive disease but with improved QoL. 
     Experiment 4 
     Survival Period of Patients of Various Groups of Cancers from the Present Study Vis-a-Vis Known Respective Survival Rates 
     Since the cohort includes cancers of different organs, further analysis of representative 16 cases was carried out and a comparison of survival data with known 5 years relative survival rate (RSR) in percentage for that particular cancer was done. This data is given below in table 10. 
     Results: 
       
     
       
         
           
               
             
               
                 TABLE 10 
               
             
            
               
                   
               
               
                 Effects of the pharmaceutical herbo-mineral-metallic composition  
               
               
                 treatment on survival period of patients of various groups of  
               
               
                 cancers vis-a-vis known respective survival rates 
               
            
           
           
               
               
               
               
               
               
            
               
                   
                   
                   
                   
                 Actual 
                   
               
               
                   
                   
                   
                 Treat- 
                 Survival 
                 5 yr 
               
               
                 Sr. 
                   
                   
                 ment 
                 period in 
                 RSR 
               
               
                 No. 
                 Diagnosis 
                 Stage 
                 period 
                 years 
                 in % 
               
               
                   
               
            
           
           
               
               
               
               
               
               
            
               
                  1 
                 CA Ovary + 
                 Ovary—IIIC (2006) 
                 3.5  
                 11.4 
                 35 
               
               
                   
                 CA Breast 
                 Breast—IA (2011) 
                 (After 
                   
                   
               
               
                   
                   
                   
                 2011) 
                   
                   
               
               
                  2 
                 CA Ovary + 
                 Ovary—IIIC (2008) 
                 1.3  
                 9.5 
                 73 
               
               
                   
                 CA Breast 
                 Breast—IA (2011) 
                 (After 
                   
                   
               
               
                   
                   
                 BRCA 1 +ve 
                 2011) 
                   
                   
               
               
                  3 
                 CA Ovary 
                 IV Local recurrence 
                 2.7 
                 3.2 
                 10 
               
               
                  4 
                 CA Ovary 
                 III/IV Locally advanced 
                 1.7 
                 5.7 
                 30 
               
               
                   
                   
                 disease 
                   
                   
                   
               
               
                  5 
                 CA Breast 
                 IV 
                 4.2 
                 4.7 
                 22 
               
               
                   
                   
                 Mets in liver and lung 
                   
                   
                   
               
               
                   
                   
                 Recurrence at site of 
                   
                   
                   
               
               
                   
                   
                 origin 
                   
                   
                   
               
               
                  6 
                 CA Tongue 
                 III 
                 3.2  
                 12.2 
                 33 
               
               
                   
                   
                 Recurrence—stage I 
                 (After 
                   
                   
               
               
                   
                   
                 (2011) 
                 2011) 
                   
                   
               
               
                  7 
                 CA Tongue 
                 III 
                 1.6 
                 4.5 
                 55 
               
               
                  8 
                 CA Colon 
                 Initial Diagnosis 
                   2  
                 9.1 
                 8 
               
               
                   
                   
                 (2006)—Stage IIA, 
                 (After 
                   
                   
               
               
                   
                   
                 Recurrence 
                 2015) 
                   
                   
               
               
                   
                   
                 (2010)—Stage I, 
                   
                   
                   
               
               
                   
                   
                 Liver Mets 
                   
                   
                   
               
               
                   
                   
                 (2011)—Stage IV, 
                   
                   
                   
               
               
                   
                   
                 Lung Mets (2014) 
                   
                   
                   
               
               
                  9 
                 CA Prostate 
                 IV 
                 1.4 
                 5 
                 3 
               
               
                   
                   
                 Bone metastasis 
                   
                   
                   
               
               
                 10 
                 CA Lung 
                 IV 
                 1.2 
                 3.1 
                 1 
               
               
                   
                   
                 Brain metastasis 
                   
                   
                   
               
               
                 11 
                 CA Lung 
                 IIA, progressively 
                   2 
                 3 
                 30 
               
               
                   
                   
                 advancing disease 
                   
                   
                   
               
               
                 12 
                 PNET* 
                 IV 
                 3.1 
                 8 
                 0 
               
               
                   
                   
                 Skeletal metastasis 
                   
                   
                   
               
               
                 13 
                 CA Stomach 
                 IIA 
                   1 
                 2.4 
                 0 
               
               
                 14 
                 AML 
                 M4≠5% blasts during 
                 6.3 
                 6.9 
                 26 
               
               
                   
                   
                 maintenance 
                   
                   
                   
               
               
                   
                   
                 chemotherapy 
                   
                   
                   
               
               
                 15 
                 Cervix 
                 IVA, Locally advanced 
                 4.8 
                 6.3 
                 57 
               
               
                   
                   
                 disease 
                   
                   
                   
               
               
                 16 
                 CA Breast 
                 IIA (2008 at initial 
                 5.7 
                 9.2 
                 26 
               
               
                   
                 with Lung 
                 diagnosis) 
                   
                   
                   
               
               
                   
                 mets 
                 IV  
                   
                   
                   
               
               
                   
                   
                 (Lung mets—in 2011) 
                   
                   
                   
               
               
                   
                   
                 TNBC 
                   
                   
                   
               
               
                   
                   
                 (A heterozygous ‘variant 
                   
                   
                   
               
               
                   
                   
                 of uncertain significance’ 
                   
                   
                   
               
               
                   
                   
                 (VUS) detected in exon 
                   
                   
                   
               
               
                   
                   
                 4 of the MSH6 gene) 
               
               
                   
               
               
                 *Peripheral Neuroectodermal tumour (CD 99 positive) in Brachial plexus 
               
            
           
         
       
     
     From table 10, it is evident that ten out of sixteen patients have surpassed the 5 years RSR reported. The overall Quality of Life of patients included in the table was remarkably well. 
     The observations reported in all the above experiments suggests that the pharmaceutical herbo-mineral-metallic composition of the present disclosure can act on the cancers of different organs and histology types and is not selective in nature for its effectiveness. It is proved to be non-toxic and does not develop resistance even when given for a period of 6 years. 
     The same studies have been carried out for the pharmaceutical herbo-mineral-metallic composition of batch 2 and batch 3. The results found to be similar like batch 1 for batch 2 and batch 3 compositions. 
     Technical Advancements 
     The present disclosure described herein above has several technical advantages including, but not limited to, the realization of the pharmaceutical herbo-mineral-metallic composition:
         that alleviates the side effects/toxicities due to chemotherapy and radiotherapy in cancer patients;   that improves overall Quality of Life of cancer patients; and   that improves disease free survival (DFS) and overall survival (OS) of cancer patients.       

     The embodiments herein and the various features and advantageous details thereof are explained with reference to the non-limiting embodiments in the following description. Descriptions of well-known components and processing techniques are omitted so as to not unnecessarily obscure the embodiments herein. The examples used herein are intended merely to facilitate an understanding of ways in which the embodiments herein may be practiced and to further enable those of skill in the art to practice the embodiments herein. Accordingly, the examples should not be construed as limiting the scope of the embodiments herein. 
     The foregoing description of the specific embodiments so fully reveal the general nature of the embodiments herein that others can, by applying current knowledge, readily modify and/or adapt for various applications such specific embodiments without departing from the generic concept, and, therefore, such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of description and not of limitation. Therefore, while the embodiments herein have been described in terms of preferred embodiments, those skilled in the art will recognize that the embodiments herein can be practiced with modification within the spirit and scope of the embodiments as described herein. 
     The use of the expression “at least” or “at least one” suggests the use of one or more elements or ingredients or quantities, as the use may be in the embodiment of the disclosure to achieve one or more of the desired objects or results. 
     Any discussion of documents, acts, materials, devices, articles or the like that has been included in this specification is solely for the purpose of providing a context for the disclosure. It is not to be taken as an admission that any or all of these matters form a part of the prior art base or were common general knowledge in the field relevant to the disclosure as it existed anywhere before the priority date of this application. 
     The numerical values mentioned for the various physical parameters, dimensions or quantities are only approximations and it is envisaged that the values higher/lower than the numerical values assigned to the parameters, dimensions or quantities fall within the scope of the disclosure, unless there is a statement in the specification specific to the contrary. 
     While considerable emphasis has been placed herein on the components and component parts of the preferred embodiments, it will be appreciated that many embodiments can be made and that many changes can be made in the preferred embodiments without departing from the principles of the disclosure. These and other changes in the preferred embodiment as well as other embodiments of the disclosure will be apparent to those skilled in the art from the disclosure herein, whereby it is to be distinctly understood that the foregoing descriptive matter is to be interpreted merely as illustrative of the disclosure and not as a limitation.